FDA approves topical solution for low testosterone
The FDA has approved testosterone topical solution CIII (Axiron) for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.
The FDA has approved testosterone topical solution CIII (Axiron) for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone.
The treatment is the first testosterone topical solution approved for application via an armpit applicator, according to manufacturers Eli Lilly and Co. and Acrux.
A phase III multicenter, open-label, 120-day clinical study demonstrated that 84% of men who completed the study achieved average serum testosterone concentration within the normal range of 300 to 1,050 ng/dL. Additionally, after 120 days of treatment, 75% of responding patients finished the study on the recommended starting dose of 60 mg.
The most common adverse reactions (incidence greater than 4%) in the study were skin application site reactions, increased red blood cell count, headache, diarrhea, vomiting, and an increase in PSA.
Dr. Chan on prevention, diagnosis, and treatment of kidney stones in pediatric patients
July 26th 2024"Stones that recur in children happen about 40% to 50% of the time. That's why the American Urological Association guidelines recommend doing a complete metabolic evaluation in all children," says Katherine Chan, MD, MPH.
